DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Alkermes - 2 Sarah Schlesinger - 2 Alex Denner - 2 Svea Herbst - 2 Bayliss - 2 Nancy Wysenski - 1 Glass Lewis - 1 Susan Langer - 1
Top related locs:
Alkermes Biogen
Top related orgs:
YORK - 2 Services - 2 Svea - 2 Thomson - 2 Capital - 1 ISS - 1 Alkermes - 1 Capital Management - 1

Search resuls for: "Sarah Schlesinger"


2 mentions found


☆ Alkermes wins battle against Sarissa in closely watched boardroom fight
  + stars: | 2023-06-29 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
NEW YORK, June 29 (Reuters) - Alkermes (ALKS.O) beat back activist investor Sarissa Capital Management's boardroom challenge on Thursday when shareholders re-elected all of the biotechnology company's directors in one of the year's most closely watched votes. But investors stuck by the company, which is valued at $5.4 billion, and returned all directors to their seats on the 11-member board. Glass Lewis, ISS's smaller rival, recommended shareholders back all Alkermes directors. Biogen shareholders this week elected Denner's romantic partner, Susan Langer, to fill his seat on the Biogen board after the board had nominated her. Both ISS and Glass Lewis referenced the Biogen matter in their recommendations on how to vote at Alkermes.
Persons: Alkermes, Nancy Wysenski, Sarah Schlesinger, Glass Lewis, Alex Denner, Susan Langer, Schlesinger, Sarissa, Svea Herbst, Bayliss, Chris Reese Organizations: YORK, Capital, Services, ISS, Svea, Thomson Locations: Alkermes, Biogen
☆ Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - sources
  + stars: | 2023-06-29 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +1 min
NEW YORK, June 29 (Reuters) - Shareholders in Alkermes have re-elected all of the biotechnology company's directors, according to two sources familiar with the matter on Thursday, dealing a blow to hedge fund Sarissa Capital Management which pushed to put three candidates on the board. Sarissa, which owns 8.5% of Alkermes, has long criticized the company's stock price and how the biotechnology company is run, and nominated three candidates, including its co-founder, Alex Denner, as director candidates to the 11-member board. But investors in the biotechnology company, which is valued at $5.3 billion, stuck by all incumbents in one of the year's most closely watched proxy contests. Representatives for the company and Sarissa could not be reached for comment. Alkermes had previously refreshed the board with new directors several times in recent years and has had success in developing and bringing new drugs to market.
Persons: Alex Denner, candiates, Sarah Schlesinger, Alkermes, Svea Herbst, Bayliss Organizations: YORK, Alkermes, Capital Management, Services, Svea, Thomson
0 next >>
Total: 2